PMD
Psychemedics Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.67
+0.00%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 19.7M | 19.7M | 22.1M | 25.2M | 24.9M |
| Cost of Revenue | 12.6M | 12.6M | 13.7M | 15.9M | 14.6M |
| Gross Profit | 7.1M | 7.1M | 8.4M | 9.3M | 10.3M |
| Operating Expenses | |||||
| R&D Expense | 749.0K | 749.0K | 1.1M | 1.3M | 1.1M |
| SG&A Expense | 8.2M | 8.2M | 10.2M | 9.0M | 8.9M |
| General & Admin Expense | 5.7M | 5.7M | 7.2M | 5.9M | 6.1M |
| Selling & Marketing Expense | 2.5M | 2.5M | 3.0M | 3.2M | 2.8M |
| Other Expenses | (3.0K) | — | — | 43.0K | — |
| Total Operating Expenses | 9.0M | 9.0M | 11.3M | 10.4M | 10.1M |
| Cost and Expenses | 21.6M | 21.6M | 25.0M | 26.3M | 24.7M |
| Operating Income (EBIT) | (1.9M) | (1.9M) | (2.9M) | (1.1M) | (3.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 49.0K |
| Interest Expense | — | 26.0K | 17.0K | — | 49.0K |
| Net Interest Income | — | (26.0K) | (17.0K) | — | — |
| Other Non-Op Income/Expense | (23.0K) | (23.0K) | (517.0K) | 43.0K | (1.0M) |
| Non-Operating Income (excl Interest) | (3.0K) | (3.0K) | 500.0K | — | — |
| EBT (Pre-Tax Income) | (1.9M) | (1.9M) | (3.4M) | (1.0M) | (821.0K) |
| Income Tax Expense | (55.0K) | (55.0K) | 716.0K | 44.0K | (156.0K) |
| Bottom Line | |||||
| Net Income | (1.9M) | (1.9M) | (4.2M) | (1.1M) | (665.0K) |
| Earnings from Cont. Ops | (1.9M) | (1.9M) | (4.2M) | (1.1M) | (665.0K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.9M) | (1.9M) | (4.2M) | (1.1M) | (665.0K) |
| Per Share | |||||
| Basic EPS | ($0.32) | ($0.32) | ($0.72) | ($0.19) | ($0.12) |
| Diluted EPS | ($0.32) | ($0.32) | ($0.72) | ($0.19) | ($0.12) |
| Revenue Per Share | $3.34 | $3.36 | $3.85 | $4.49 | $4.49 |
| Shares | |||||
| Basic Shares Outstanding | 5.9M | 5.9M | 5.7M | 5.6M | 5.5M |
| Diluted Shares Outstanding | 5.9M | 5.9M | 5.7M | 5.6M | 5.5M |
| Profitability Metrics | |||||
| EBITDA | (262.0K) | 191.0K | (751.0K) | 2.2M | 3.9M |
| D&A | 1.6M | 2.1M | 2.7M | 3.3M | 3.7M |
| EBIT | (1.9M) | (1.9M) | (3.4M) | (1.1M) | 209.0K |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2024